The BRAF V600E mutation detected by immunostaining or molecular studies is expected in ganglioglioma but can be positive in many other tumors, including low-grade glioma, PXA, DNT, and other glioneuronal tumors [14]. This evidence concerns the gene BRAF and pleomorphic xanthoastrocytoma.